#biogen
Latest news and interesting information about biogen.
Compass Pathways Elects Kathleen Tregoning to Board
Compass Pathways elects Kathleen Tregoning to its board. The company advances COMP360 psilocybin therapy for depression with Phase 3 success.
Wolfe Research Reaffirms Ionis Stock Outperform Rating
Wolfe Research reiterates Outperform rating on Ionis Pharmaceuticals stock. Analysis of Arrowhead competition and financial results.
Denali stock drops after Parkinson drug fails trial
Denali Therapeutics stock falls after Parkinson's drug BIIB122 fails Phase 2b trial. Shares drop 2.9% premarket.
Piper Sandler Raises Biogen Target to $225
Piper Sandler raises Biogen price target to $225 from $214. Phase II trial of BIIB080 missed primary endpoint but showed slowing of clinical decline at lowest dose.
Biogen Stock: Alzheimer Drug Shows Promise
Biogen's Alzheimer drug diranersen shows positive Phase 2 results. Stock analysis and future outlook from Bond.az.
Jefferies Reiterates Buy on Biogen Stock
Jefferies reiterates Buy rating on Biogen stock with $210 target following promising Phase II Alzheimer's data.
Biogen Stock Rises as Stifel Maintains Buy
Biogen stock rises as Stifel maintains buy rating. Updates on Alzheimer's drug trial and financial results.
...